WAYNE, Pa., July 26, 2017 /PRNewswire/ -- Egalet
Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty
pharmaceutical company focused on developing, manufacturing and
commercializing innovative treatments for pain and other
conditions, today announced that its second quarter financial
results will be released on Wednesday,
August 9, 2017.
The company will host a live conference call and webcast at
4:30 p.m. Eastern Time to review the
company's financial and operating results and provide a general
business update.
Interested parties may listen to the call via a live audio
webcast which may be accessed by visiting Egalet.com. Please
connect to the website a few minutes prior to the live webcast to
ensure adequate time for any software download that may be needed
to access the webcast. Individuals also may participate in the call
by dialing 1-888-346-2615 (domestic) or 1-412-902-4253
(international) and asking for the "Egalet Earnings
Call." The replay will be available approximately two
hours after the call on Egalet.com.
About Egalet
Egalet, a fully integrated specialty
pharmaceutical company, is focused on developing, manufacturing and
commercializing innovative treatments for pain and other
conditions. Egalet has three approved products:
ARYMO® ER (morphine sulfate) extended-release
tablets for oral use —CII, developed using Egalet's proprietary
Guardian™ Technology, OXAYDO® (oxycodone HCI, USP)
tablets for oral use only –CII and SPRIX® (ketorolac
tromethamine) Nasal Spray. Using Guardian Technology, Egalet is
developing a pipeline of clinical-stage, product candidates
including Egalet-002, an abuse-deterrent, extended-release, oral
oxycodone formulation for the management of pain severe enough to
require daily, around-the-clock, long-term opioid treatment and for
which alternative treatment options are inadequate. Guardian
Technology can be applied broadly across different classes of
pharmaceutical products and can be used to develop combination
products that include multiple active pharmaceutical ingredients
with similar or different release profiles. For full prescribing
information on ARYMO ER, including the boxed warning and medication
guide, please visit arymoer.com. For full prescribing information
on SPRIX, including the boxed warning and medication guide, please
visit sprix.com. For full prescribing information on OXAYDO,
including the boxed warning and medication guide, please visit
oxaydo.com.
Investor and Media Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
Email: bcs@egalet.com
Tel: 484-259-7370
View original content with
multimedia:http://www.prnewswire.com/news-releases/egalet-to-host-conference-call-and-webcast-on-august-9-2017-to-discuss-second-quarter-2017-financial-results-300493329.html
SOURCE Egalet Corporation